|
Abstract
|
Abstract
Purpose: Breast cancer (BC) is globally the main reason of cancer-related deaths in women.
Omentin-1, an anti-inflammatory and antioxidant adipokine, plays different roles in
tumorigenesis and anti-oncogenic pathways. In present study, we investigated the association of
omentin-1 with oxidative stress and clinical significances in healthy controls and BC patients to
assess the prognostic and diagnostic value of omentin-1 in this cancer.
Methods: This case-control study included 88 BC patients and 86 healthy controls. The serum
levels of omentin-1 were assessed by enzyme-linked immunosorbent assays methods. Also,
total antioxidant capacity (TAC), total oxidant status (TOS) and malondialdehyde (MDA) serum
levels were measured by spectrophotometer. quantitative real-time polymerase chain reaction
(qRT-PCR) was applied to the measurement of gene expression of omentin-1.
Results: the serum levels of omentin-1 were significantly lower in the BC patients compared
to the healthy controls (P < 0.001). Moreover, gene expression of omentin-1was significantly
downregulated in the BC tissues compared to the adjacent normal tissues (P < 0.001). Gene
expression of omentin-1and its serum levels were significantly higher in grade I compared with
grade II and III (P = 0.001, P < 0.001, respectively). Additionally, the serum levels of omentin-1
in the p53-positive BC patients were significantly higher than the p53-negative BC patients
(P = 0.001). There was an inverse correlation between the serum levels of MDA and TOS with
the serum levels of omentin-1 (r=-0.436, r=-461, respectively).
Conclusion: We conclude that omentin-1 may have a good prognostic and diagnostic roles in
the BC patients and decreases oxidative stress in these patients.
|